Editorial Comment
Patients with advanced heart failure (HF) have high mortality rates, to a relatively greater extent in those with New York Heart Association (NYHA) functional class IV versus III, justifying consideration of cardiac transplantation in this high-risk population.
1,2 For many of these patients, gains in pharmacologic therapy have helped significantly in delaying progression to transplantation requirement. However, even with the advent of angiotensin converting enzyme inhibitors, beta blockers, and aldosterone antagonists, overall attrition in the advanced HF population is still substantial.
Device therapy, first with implantable cardioverter defibrillators (ICDs) and, more recently, with cardiac resynchronization (CRT) or combination (CRT-D) devices, has provided documented survival benefit (or at least clinical benefit [the initial CRT trials]) beyond medical therapy alone in the advanced HF population. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] For clinical decision making and cost effectiveness considerations, it would be important to understand the extent to which NYHA functional class III and IV patients respond similarly or differentially to device therapy. Such understanding is hampered, however, by the relative paucity of information on outcomes with device therapy in the latter HF patient group.
Limited Controlled Trial Data on Device Therapy in NYHA Class IV Patients
The accompanying Table 1 lists 13 randomized clinical trials investigating outcomes of device therapy in patients (at least 100 enrollees per study), all of whom had baseline left ventricular (LV) systolic dysfunction (LV ejection fraction [LVEF] typically ≤ 0.35); those in the various CRT/CRT-D trials typically had additional objective evidence for HF besides reduced LVEF and high functional class. Patients in the 13 trials had mostly ischemic cardiomyopathy (72% of ICD-only studies; and 54% of CRT/CRT-D studies). Of note, NYHA functional class IV patients constituted only 4.2% of the total of 10,803 patients enrolled in these trials (1% of ICD-only studies; and 10% of CRT/CRT-D studies). In contrast, NYHA class III patients constituted 9-30% of ICD-only trials; and 72-100% of CRT/CRT-D trials. [VF] by the treating electrophysiologist) at the relatively brief 6-month follow-up point. By multivariable analysis, the only independent predictors of appropriate ICD therapy were NYHA class and type of ICD indication (secondary vs. primary prevention): appropriate ICD therapy delivery was significantly greater in patients with NYHA class IV symptoms versus the other two classes, and in patients with a history of spontaneous ventricular tachyarrhythmias (secondary prevention group) versus those with inducible sustained VT (primary prevention, MADIT patient profile). Even after exclusion of NYHA class II patients, appropriate ICD therapy delivery at 6 months was 86% more likely to occur in NYHA class IV versus class III patients (∼37% vs. ∼19% incidences rates, respectively; P < 0.04). This finding was independent of patient age, gender, LVEF, etiology of cardiomyopathy (ischemic vs. other) or type of HF medication used.
The authors' observations seem at variance with a body of data showing, proportionately, a much greater mortality from sudden cardiac death (SCD; presumably mediated principally by ventricular tachyarrhythmias) in NYHA class III versus class IV HF patients (∼60% vs. ∼ 20-33%, respectively).
1,2,17 Moreover, the crude SCD rate (actual number of SCDs per number of individuals at risk) in class IV patients is actually less than 1 or equal to 2 that of class III patients. Thus, the much greater incidence of appropriate ICD therapy delivery in class IV versus class III patients, as reported by Desai et al., 16 appears paradoxical. One might attempt to dismiss this seeming discrepancy by invoking non-equivalence between appropriate ICD therapy and aborted SCD events. While such a distinction is true in general, there are several problems with applying this argument in the case of an advanced HF population. For one thing, the notion that appropriate ICD shocks in these patients often represent brief episodes of non-sustained VT (or VF) is not that tenable in an era of non-committed ICDs that take a "second look" after capacitor charging, just prior to shock delivery. 18 (Conceivably, some of the appropriate ICD therapies in the class IV patients of Desai et al. may have reflected antitachycardia pacing for relatively slow, tolerated non-sustained or sustained VTs, but the authors do not provide data on programmed tiered therapy configurations, or types of appropriate therapies delivered and their associated stored electrograms.) The alternative postulation that many ICD therapy events in the class IV patients may have resulted from sustained VTs that would have (eventually) terminated spontaneously-based on observations from the DEFINITE trial, 19 limited to non-ischemic cardiomyopathy patients of NYHA classes I-III-overlooks the fact that such protracted tachyarrhythmias in class IV patients, especially those with ischemic cardiomyopathy (the predominant pathology in the series of Desai et al.) , are less likely to be tolerated than in class III patients and carry significant risk of degeneration to VF (i.e., SCD). Moreover, studies of patients receiving an ICD (mostly for secondary prevention), while they await cardiac transplantation, show the following: (a) a 6-month appropriate ICD shock rate of similar order of magnitude to the ICD therapy rate reported by the authors for their class IV patients 20, 21 ; (b) equivalence between appropriate ICD therapy and incidence of SCD, as evident from a comparison of survival curves for transplant-listed patients with versus without an ICD 21 ; and, (c) absence of SCD events among transplant-listed ICD implantees versus non-implantees. 21, 22 Thus, the greater frequency of appropriate ICD therapy delivery in class IV versus class III patients, as reported by Desai et al., would seem to largely represent a true difference in the incidence of potentially life-threatening ventricular tachyarrhythmic events, at least over the 6-month follow-up period.
Factors Influencing Incidence of Appropriate ICD Therapy Delivery in CRT-D Implantees
In trying to understand the finding of the authors, it is important to consider a number of factors that are operative in CRT-D treated patients.
Prolonged QRS Duration as Inclusion Criterion for CRT Therapy (with or without Defibrillator Capability)
As demonstrated in the large CHF-STAT amiodarone trial database, 23, 24 taking a population of patients with LV dysfunction (LVEF ≤ 0.40, predominantly NYHA classes II and III, 4% class IV) and then subselecting those with QRS duration ≥ 120 ms (i.e., 290 of 669 = 43% of the study cohort) increases the crude SCD rate to nearly 25% from 21% in the parent population; one can further calculate that the corresponding crude rate of pump failure deaths increases to 15% from 11% and that, consequently, crude total cardiac mortality rises to 40% from 32%, respectively (working backward from the total mortality data for the restricted QRS duration population 24 and assuming an unchanged overall 9% rate of non-cardiac or unclassified deaths 23 ). How the magnitude of changes in mortality rates consequent to the requirement of prolonged QRS duration for CRT-D eligibility would play out in NYHA class IV versus class III patients-with potential differential quantitative impact on rates of appropriate ICD therapy-remains to be determined.
Effect of CRT
Whereas screening for CRT or CRT-D implantation eligibility according to QRS duration selects a subset of advanced HF patients with increased SCD and pump failure mortality, once the device is implanted, its CRT function then acts in the opposite direction to decrease these mortality rates. 14, 15 Whether or not such opposing effects on cardiac mortality completely cancel out and whether the net effect may differ by pre-existing functional class is not yet known. It has been reported by Lecoq et al., 25 however, that at 6 months, a similar proportion (∼80%) of NYHA class III and class IV patients were clinical responders to CRT; and another study 26 found that early improvements in HF parameters were maintained during CRT for at least 3 years. Two recent observational studies 27, 28 offer concordant evidence that CRT therapy can also decrease the incidence of appropriate ICD therapy. If confirmed by additional studies, it would be of interest to investigate whether such a favorable response may be influenced by pre-CRT functional class. For example, maybe the differential incidence of appropriate ICD therapy reported by Desai et al. 16 results from a more marked reduction in tachyarrhythmic event rates in functional class III versus class IV patients.
Study Limitations
It is important to emphasize that the Ventak CHF/Contak CD patient population studied by the authors was a tachyarrhythmia-event-prone group by virtue of the fact that three-fourths of them had spontaneous sustained ventricular tachyarrhythmias and the other one-fourth had inducible sustained ventricular tachyarrhythmias. Whether the observed disparate incidence rates of appropriate ICD therapy according to functional class represents a more generalizable phenomenon, that would also occur when CRT-D devices are implanted in advanced HF patients without spontaneous or inducible sustained ventricular tachyarrhythmias (as in COMPANION 14 ), remains to be determined. The issue of the potential confounding effect of absolute QRS duration (and, ideally, more informative measures of left ventricular dyssynchrony 29 ) also must be considered. For CRT or CRT-D therapy, both COMPANION 14 and CARE-HF 15 reported a trend toward greater benefit, as per the composite endpoint of all-cause mortality or hospitalization (and similarly for all-cause mortality with CRT-D alone in COM-PANION), in those patients who had more prolonged QRS durations. In the study of Desai et al., 16 a QRS duration of > 160 ms was associated with a hazard ratio of 1.29 for appropriate ICD therapy, but at a P value of 0.13 (possibly reflecting reduced power, and just over the usual cutoff [≤ 0.10] for incorporation into multivariable analyses). Since QRS duration was not included in the multivariable analysis, we do not know the extent to which the impact of NYHA class IV as a predictor of appropriate ICD therapy might have been diluted (note modest P value of <0.02). To confirm and strengthen the authors' observations, therefore, future studies are needed that will incorporate into their design a larger number of class IV patients; measures of additional outcome predictors in HF; detailed analyses of appropriate ICD therapy events; echocardiographic measures of left ventricular dyssynchrony; and a longer follow-up period (at least 1-2 years).
Implications
Assuming the findings of Desai et al. 16 are confirmed, what implications would this have for managing advanced HF patients? It is recognized that NYHA functional class labels in these patients may vary over time, particularly when considering degrees of class III (i.e., IIIa and IIIb) and episodic decompensations (transient "class IV"). If the simple "class IV"-versus "class III"-label truly implies a greater incidence of appropriate ICD therapy in CRT-D recipients, the pertinent clinical question raised is whether this translates into a greater number of days of life saved. In COMPAN-ION, 14 there was no clear difference in the magnitude of CRT-D-associated reduction in all-cause mortality for patients labeled as class IV versus class III; corresponding data from CARE-HF (limited to CRT alone) have not been published. Although COMPANION documented a favorable cost-effectiveness ratio for CRT and CRT-D, 30 only 14% of that trial's enrollees had class IV symptoms. The potential clinical relevance of the findings of Desai et al. will only emerge in the context of a greater understanding of the impact of CRT and CRT-D on survival, and the broader issue of cost effectiveness of such therapies, in HF studies with more substantial representation of class IV patients.
